Oncology Examination: Difference between revisions

No edit summary
No edit summary
Line 12: Line 12:


== Introduction ==
== Introduction ==
Various domains of examination with related tools are included on this page according to the International Classification Framework Model for Assessment in Oncology Rehabilitation by Gilchrist LS, Galantino ML, Wampler M, et al.<ref name="Oncology Framework">Gilchrist LS, Galantino ML, Wampler M, Marchese VG, Morris GS, Ness KK. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967778/ A framework for assessment in oncology rehabilitation]. Physical Therapy. 2009 Mar 1;89(3):286-306.</ref>:
A study <ref name="Oncology Framework">Gilchrist LS, Galantino ML, Wampler M, Marchese VG, Morris GS, Ness KK. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967778/ A framework for assessment in oncology rehabilitation]. Physical Therapy. 2009 Mar 1;89(3):286-306.</ref> was published before to guide rehabilitation therapists who provide [[Oncology Rehabilitiation|oncology rehabilitation]] to choose appropriate outcome measures that are relevant to the three human function domains (body functions and structure, activities, and participation) of the [[International Classification of Functioning, Disability and Health (ICF)|International Classification Framework]] (ICF) developed by the World Health Organisation (WHO).


* Mental Function
In this study, outcome measures are grouped according to ICF domains as shown in the table:
* Sensory Functions &amp; Pain  
{| class="wikitable"
* Neuromusculoskeletal Function &amp; Movement-Related Functional Assessment
|+Table 1: Measurement Tools For ICF Domains
* Functions of Body Systems
!'''Measurement of Body Function and Structure'''
* Red and Yellow Flag Measures &amp; Risk Patterns
!'''Measurement of Activity and Participation'''
* Functional Activities, Mobility &amp; Self-Care
|-
* Psychosocial
|Mental Functions
|Mobility
|-
|Sensory Functions and Pain
|Self-care
|-
|Neuromusculoskeletal and Movement-Related Functions and Structures
|Domestic Life, Interpersonal Relations, and Major Life Areas
|-
|Functions of the Cardiovascular, Hematologic, Immunologic, and Respiratory Systems
|
|-
|Diagnostic Measures of Body Function and Structure Indicating “Red Flags” or “Yellow Flags” for Physical Therapists
|}


== Mental Function ==
== Measurement of Body Function and Structure ==


=== Mental Function ===
* Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system. <ref name="Breast Cancer Cognitive Dysfunction">Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.</ref><ref>Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.</ref><ref>Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.</ref>
* Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system. <ref name="Breast Cancer Cognitive Dysfunction">Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.</ref><ref>Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.</ref><ref>Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.</ref>
* Mental impairments can be induced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage. <ref>Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493</ref>
* Mental impairments can be induced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage. <ref>Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493</ref>
Line 33: Line 47:
* Profile of Mood States <ref>Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45–53.</ref>
* Profile of Mood States <ref>Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45–53.</ref>


== Sensory Functions &amp; Pain ==
=== Sensory Functions &amp; Pain ===
Sensory functions may be affected by neoplasms such as a <span style="line-height: 1.5em;">Vestibular Schwannoma which may cause unilateral dysfunction</span> <span style="line-height: 1.5em;">or chemotherapy drugs such as</span> Cisplastin.  
Sensory functions may be affected by neoplasms such as a <span style="line-height: 1.5em;">Vestibular Schwannoma which may cause unilateral dysfunction</span> <span style="line-height: 1.5em;">or chemotherapy drugs such as</span> Cisplastin.  


Line 47: Line 61:
* [https://physio-pedia.com/Brief_Pain_Inventory_-_Short_Form Brief Pain Inventory]
* [https://physio-pedia.com/Brief_Pain_Inventory_-_Short_Form Brief Pain Inventory]


== Neuromusculoskeletal Function &amp; Movement-Related Functional Assessment ==
=== Neuromusculoskeletal Function &amp; Movement-Related Functional Assessment ===
Peripheral Neuropathies (chemotherapy induced), Anesthesia/Dysesthesias (with compression or surgical dissection of nerves), Motor Function Loss and Radiation Plexopathy, range of motion limitation (due to scar tissue formation after surgical resections, chemotherapy or radiation therapy and fibrosis after irradiation) may occur.
Peripheral Neuropathies (chemotherapy induced), Anesthesia/Dysesthesias (with compression or surgical dissection of nerves), Motor Function Loss and Radiation Plexopathy, range of motion limitation (due to scar tissue formation after surgical resections, chemotherapy or radiation therapy and fibrosis after irradiation) may occur.
Muscle functions can be affected by any of the following:
Muscle functions can be affected by any of the following:
Line 70: Line 84:
* Gait: Kinematic Analysis, Gait Speed Measurements, Tinetti Balance &amp; Gait Scale
* Gait: Kinematic Analysis, Gait Speed Measurements, Tinetti Balance &amp; Gait Scale


== Functions of Body Systems ==
=== Functions of Body Systems ===
 
===Cardiovascular ===


==== Cardiovascular ====
*Cardiotoxicity can be a late effect of chemotherapy due damage of the cardiac myoctyes ultimately resulting in congestive heart failure.  
*Cardiotoxicity can be a late effect of chemotherapy due damage of the cardiac myoctyes ultimately resulting in congestive heart failure.  
*Radiation may scar the cardiac and coronary arteries resulting in restrictive coronary disease.
*Radiation may scar the cardiac and coronary arteries resulting in restrictive coronary disease.
Line 81: Line 94:
*Echocardiogram to assess ventricular function, cardiac motion and output.
*Echocardiogram to assess ventricular function, cardiac motion and output.


===Hematologic===
==== Hematologic ====
'''Outcome Measure:'''
'''Outcome Measure:'''


Complete blood count
Complete blood count


===Immunologic===
==== Immunologic ====
 
* Damage to lymph vessels by tumor obstruction, surgical resection of lymph nodes, radiation leading to fibrosis of the lymph vessels.
* Damage to lymph vessels by tumor obstruction, surgical resection of lymph nodes, radiation leading to fibrosis of the lymph vessels.


Line 95: Line 107:
*Water Displacement Method of measuring limb volume
*Water Displacement Method of measuring limb volume


===Integumentary===
==== Integumentary ====
 
* With [[lymphoedema]], skin breakdown or infection can occur.
* With [[lymphoedema]], skin breakdown or infection can occur.


Line 102: Line 113:
*[http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf National Cancer Institue's Common Termonology Criteria for Adverse Events] (Lymphatic, Integumentary Systems): Uses Grades to assess severity of different conditions for example Lymphedema
*[http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf National Cancer Institue's Common Termonology Criteria for Adverse Events] (Lymphatic, Integumentary Systems): Uses Grades to assess severity of different conditions for example Lymphedema


===Respiratory===
==== Respiratory ====
 
*Lung tumors may limit thoracic cavity expansion, compress the airways or reduce the surface area of the lung.
*Lung tumors may limit thoracic cavity expansion, compress the airways or reduce the surface area of the lung.
*Chemotherapy agents (beomycin, methotrexate and docetaxel) may damage pneumocytes. This reduces alveoli and air exchange.
*Chemotherapy agents (beomycin, methotrexate and docetaxel) may damage pneumocytes. This reduces alveoli and air exchange.
Line 115: Line 125:
* [https://physio-pedia.com/Borg_Rating_Of_Perceived_Exertion Borg Rating of Perceived Exertion]
* [https://physio-pedia.com/Borg_Rating_Of_Perceived_Exertion Borg Rating of Perceived Exertion]


== Red and Yellow Flag Measures &amp; Risk Patterns ==
=== Red and Yellow Flag Measures &amp; Risk Patterns ===
 
# Sites at Risk for Neural Compression:
# Sites at Risk for Neural Compression:


Line 148: Line 157:
*Thrombocytopenia
*Thrombocytopenia


== Functional Activities, Mobility &amp; Self-Care ==
== Measurement of Activity and Participation ==
 
=== Functional Activities, Mobility &amp; Self-Care ===
'''Outcome measures for mobility assessment:'''
'''Outcome measures for mobility assessment:'''


Line 172: Line 183:
*Disability of Arm, Shoulder and Hand (DASH) questionnaires.
*Disability of Arm, Shoulder and Hand (DASH) questionnaires.


== Psychosocial ==
=== Psychosocial ===
 
* Consider the patients domestic life, interpersonal relations and major life areas.
* Consider the patients domestic life, interpersonal relations and major life areas.
* Assess participation in or attending community activities, reduced job expectations, etc.
* Assess participation in or attending community activities, reduced job expectations, etc.

Revision as of 22:30, 26 November 2023

This article is currently under review and may not be up to date. Please come back soon to see the finished work! (17/11/2023)


Introduction[edit | edit source]

A study [1] was published before to guide rehabilitation therapists who provide oncology rehabilitation to choose appropriate outcome measures that are relevant to the three human function domains (body functions and structure, activities, and participation) of the International Classification Framework (ICF) developed by the World Health Organisation (WHO).

In this study, outcome measures are grouped according to ICF domains as shown in the table:

Table 1: Measurement Tools For ICF Domains
Measurement of Body Function and Structure Measurement of Activity and Participation
Mental Functions Mobility
Sensory Functions and Pain Self-care
Neuromusculoskeletal and Movement-Related Functions and Structures Domestic Life, Interpersonal Relations, and Major Life Areas
Functions of the Cardiovascular, Hematologic, Immunologic, and Respiratory Systems
Diagnostic Measures of Body Function and Structure Indicating “Red Flags” or “Yellow Flags” for Physical Therapists

Measurement of Body Function and Structure[edit | edit source]

Mental Function[edit | edit source]

  • Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system. [2][3][4]
  • Mental impairments can be induced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage. [5]
  • Emotional Functions may also affect the ability of our patients to respond to and/or participate in physical therapy.

Outcome Measures:

Sensory Functions & Pain[edit | edit source]

Sensory functions may be affected by neoplasms such as a Vestibular Schwannoma which may cause unilateral dysfunction or chemotherapy drugs such as Cisplastin.

Outcome Measures For Sensory Functions:

  • Dizziness Handicap Inventory Questionnaire: 25 items assess the impact of disequilibrium on functional activities.[7]

Outcome Measures For Pain:

Neuromusculoskeletal Function & Movement-Related Functional Assessment[edit | edit source]

Peripheral Neuropathies (chemotherapy induced), Anesthesia/Dysesthesias (with compression or surgical dissection of nerves), Motor Function Loss and Radiation Plexopathy, range of motion limitation (due to scar tissue formation after surgical resections, chemotherapy or radiation therapy and fibrosis after irradiation) may occur. Muscle functions can be affected by any of the following:

  • Muscle weaknesses from inflammatory intermediates produced by the tumor that are catabolic and cause muscle wasting (cachexia).
  • Surgical denervation or damage
  • Radiation & Chemotherapy can damage muscle or nerve tissue. (Vinca alkaloids, taxanes and platinum agents)

Balance dysfunction can be caused from any of the following:

  • Sensory input
  • Central processing of balance-related information
  • Range of motion limitations
  • Orthostatic hypotension
  • Muscle weakness
  • Peripheral neuropathies from taxane

Outcome Measures:

Functions of Body Systems[edit | edit source]

Cardiovascular[edit | edit source]

  • Cardiotoxicity can be a late effect of chemotherapy due damage of the cardiac myoctyes ultimately resulting in congestive heart failure.
  • Radiation may scar the cardiac and coronary arteries resulting in restrictive coronary disease.

Outcome Measure:

  • Echocardiogram to assess ventricular function, cardiac motion and output.

Hematologic[edit | edit source]

Outcome Measure:

Complete blood count

Immunologic[edit | edit source]

  • Damage to lymph vessels by tumor obstruction, surgical resection of lymph nodes, radiation leading to fibrosis of the lymph vessels.

Outcome Measures:

  • Limb Circumfrence Measurements Pre-op and Post-op
  • Water Displacement Method of measuring limb volume

Integumentary[edit | edit source]

  • With lymphoedema, skin breakdown or infection can occur.

Outcome Measure:

Respiratory[edit | edit source]

  • Lung tumors may limit thoracic cavity expansion, compress the airways or reduce the surface area of the lung.
  • Chemotherapy agents (beomycin, methotrexate and docetaxel) may damage pneumocytes. This reduces alveoli and air exchange.
  • Patients are then at risk for pneumonitis or fibrosis.

Outcome Measures:

Red and Yellow Flag Measures & Risk Patterns[edit | edit source]

  1. Sites at Risk for Neural Compression:
  • Brachial Plexus: Breast & Lung Tumors
  • Lumbosacral Plexus: Colorectal & Gynecological Tumors, Sarcomas & Lymphomas

Symptoms: Unrelenting pain, worse at night progressing to focal sensory loss or weakness

2. Cancers that often metastasize to the spine:

  • Prostate
  • Breast
  • Lung
  • Colon

3. Cancers that often present in the femur:

  • Sarcoma

4. Cancer and it's treatment increases risk for osteonecrosis in the following regions:

  • Proximal or Distal Femur
  • Proximal Humerus
  • Jaw
  • Metatarsals

5. Other Risks:

  • Osteoporosis
  • Neutropenia
  • Thrombocytopenia

Measurement of Activity and Participation[edit | edit source]

Functional Activities, Mobility & Self-Care[edit | edit source]

Outcome measures for mobility assessment:

  • Functional Mobility Assessment: Requires patients to physically perform specific tasks and to answer questions, quantifying their level of function.
  • The Toronto Extremity Salvage Score, lower-extremity version is a self administered questionnaire that ask patients to indicate the level of difficulty they experience in dressing, grooming, mobility, work, sports, and leisure.
  • Changing and maintaining body positions
  • Carrying
  • Moving and handling objects
  • Walking
  • Moving around using transportation


Outcome measures for self-care:

  • Karnofsky Performance Scale: A standard measure of the ability of adult patients with cancer to perform ordinary tasks. scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities
  • Barthel Index: Includes multiple components and diverse self-care activities. May be more responsive in rehabilitation.
  • Performance or self-report measure of independence in basic activities of daily living

Shoulder measures for breast cancer: [9]

  • The Functional Assessment of Cancer Therapy Breast (FACT-B+4)
  • Disability of Arm, Shoulder and Hand (DASH) questionnaires.

Psychosocial[edit | edit source]

  • Consider the patients domestic life, interpersonal relations and major life areas.
  • Assess participation in or attending community activities, reduced job expectations, etc.

Outcome Measures:

  • Reintegration to Normal Living Index: Measures adults' perception of their ability to resume life roles after trauma or illness

References[edit | edit source]

  1. Gilchrist LS, Galantino ML, Wampler M, Marchese VG, Morris GS, Ness KK. A framework for assessment in oncology rehabilitation. Physical Therapy. 2009 Mar 1;89(3):286-306.
  2. Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.
  3. Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.
  4. Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.
  5. Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493
  6. Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45–53.
  7. Jacobson G, Newman C, Hunter L, Balzer G. Balance function test correlates of the Dizziness Handicap Inventory. J Am Acad Audiol. 1991;2:253–260.
  8. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61:fckLR1297–1300.
  9. Davies C, Ryans K, Levenhagen K, Perdomo M. Quality of Life and Functional Outcome Measures for Secondary Lymphedema in Breast Cancer Survivors. Rehabil Oncol Vol 32 (1)p. 7-12